Preserving CTLA-4 immune checkpoint for safer and more effective cancer immunotherapy

保留 CTLA-4 免疫检查点以实现更安全、更有效的癌症免疫治疗

基本信息

  • 批准号:
    10669173
  • 负责人:
  • 金额:
    $ 51.31万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-08-07 至 2025-07-31
  • 项目状态:
    未结题

项目摘要

Summary Combination therapy with anti-CTLA-4 and anti-PD-1 mAbs has emerged as the most potent and durable cancer immunotherapy. However, the autoimmune adverse effect associated with the combination therapy is considerably more severe, with 50-90% of melanoma patients developing grade 3 and 4 immunotherapy-related adverse effect. A major challenge in cancer immunotherapy is how to reduce adverse effects of the combination therapy without affecting therapeutic efficacy. This is in part related to the fact that the mechanism by which combination therapy exacerbate irAE is not well understood. To address this issue, we have developed a novel model in which combination therapy with anti-mouse PD-1 in conjunction with either Ipilimumab or Tremelizumab recapitulates the severe irAE observed in clinic. Importantly, different anti- human CTLA4 antibodies differ dramatically in irAE in this preclinical model. We have carried out extensive preliminary studies to elucidate the molecular basis of irAE-prone vs non-prone antibodies and have shown the antibody-mediated degradation of membrane-associated CTLA-4 as a major feature of irAE-prone antibodies. Meanwhile, it has long been established that soluble CTLA-4 (sCTLA4) molecule is protective against autoimmune diseases in the mice. We have obtained data that showed strong correlation between the levels of sCTLA4 and irAE in the clinic. We further established a striking correlation between high binding to soluble CTLA4 protein and the severity of irAE in human CTLA4KI mice. Based on these unexpected observations and the strong therapeutic effect of CTLA4-Fc (Abatacept, marketed as Orencia) for autoimmune diseases including irAE, we hypothesize that both cell surface and sCTLA-4 confers protection against irAE and that sCTLA4 that evades clearance by irAE-inducing anti-CTLA-4 antibodies is a potential therapeutic for prevention and treatment of irAE. Our proposal challenges the prevailing paradigm that autoimmunity and cancer immunity are based on the same mechanism and thus intrinsically linked. More importantly, our work will have a transforming impact in immune-oncology research, as it may offer prophylactic and treatment for irAEs associated with the most effective immunotherapy in use in the clinic.
总结 使用抗CTLA-4和抗PD-1 mAb的组合疗法已经成为最有效和最有效的治疗方法。 持久的癌症免疫疗法。然而,与联合用药相关的自身免疫性不良反应 治疗相当严重,50-90%的黑素瘤患者发展为3级和4级 免疫治疗相关副作用。癌症免疫治疗的一个主要挑战是如何减少不良反应。 在不影响治疗效果的情况下,这在一定程度上与以下事实有关: 联合治疗加重irAE的机制还不清楚。为了解决这个问题, 我们已经开发了一种新的模型,其中抗小鼠PD-1联合 伊匹单抗或曲美珠单抗概括了临床上观察到的严重irAE。重要的是,不同的抗- 在该临床前模型中,人CTLA 4抗体在irAE中显著不同。我们进行了广泛的 初步研究阐明了irAE倾向性抗体与非倾向性抗体的分子基础, 抗体介导的膜相关CTLA-4的降解是易发生irAE的抗体的主要特征。 同时,长期以来已经确定可溶性CTLA-4(sCTLA 4)分子对抗肿瘤具有保护性, 小鼠的自身免疫性疾病。我们已经获得的数据表明, sCTLA 4和irAE的临床应用。我们进一步建立了高结合与可溶性 CTLA 4蛋白和人CTLA 4KI小鼠中irAE的严重程度。根据这些意想不到的观察, CTLA 4-Fc(阿巴西普,作为Orencia销售)对自身免疫性疾病的强治疗效果 包括irAE,我们假设细胞表面和sCTLA-4都能提供抗irAE的保护, 逃避irAE诱导的抗CTLA-4抗体清除的sCTLA-4是一种潜在的治疗药物, 预防和治疗irAE。 我们的建议挑战了自身免疫和癌症免疫所基于的流行范式 相同的机制,因此内在联系。更重要的是,我们的工作将产生变革性的影响, 在免疫肿瘤学研究中,因为它可以为与大多数 有效的免疫疗法在临床上的应用。

项目成果

期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
CTLA-4 antibody-drug conjugate reveals autologous destruction of B-lymphocytes associated with regulatory T cell impairment.
CTLA-4 抗体-药物偶联物揭示了与调节性 T 细胞损伤相关的 B 淋巴细胞的自体破坏。
  • DOI:
    10.1101/2023.03.01.530608
  • 发表时间:
    2023
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Muthana,MuslehM;Du,Xuexiang;Liu,Mingyue;Wang,Xu;Wu,Wei;Ai,Chunxia;Su,Lishan;Zheng,Pan;Liu,Yang
  • 通讯作者:
    Liu,Yang
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Lishan Su其他文献

Lishan Su的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Lishan Su', 18)}}的其他基金

Immune Mechanisms of Elevated Liver Diseases During HIV Infection
HIV 感染期间肝病升高的免疫机制
  • 批准号:
    10461881
  • 财政年份:
    2021
  • 资助金额:
    $ 51.31万
  • 项目类别:
Immune Mechanisms of Elevated Liver Diseases During HIV Infection
HIV 感染期间肝病升高的免疫机制
  • 批准号:
    10240509
  • 财政年份:
    2021
  • 资助金额:
    $ 51.31万
  • 项目类别:
Immune Mechanisms of Elevated Liver Diseases During HIV Infection
HIV 感染期间肝病升高的免疫机制
  • 批准号:
    10359221
  • 财政年份:
    2021
  • 资助金额:
    $ 51.31万
  • 项目类别:
Preserving CTLA-4 immune checkpoint for safer and more effective cancer immunotherapy
保留 CTLA-4 免疫检查点以实现更安全、更有效的癌症免疫治疗
  • 批准号:
    10457311
  • 财政年份:
    2020
  • 资助金额:
    $ 51.31万
  • 项目类别:
HIV-1 Vpr disrupts the IFN-TET-ISG pathway to promote HIV-1 infection and persistence
HIV-1 Vpr 破坏 IFN-TET-ISG 通路,促进 HIV-1 感染和持续存在
  • 批准号:
    10371668
  • 财政年份:
    2016
  • 资助金额:
    $ 51.31万
  • 项目类别:
HIV-1 Vpr disrupts the IFN-TET-ISG pathway to promote HIV-1 infection and persistence
HIV-1 Vpr 破坏 IFN-TET-ISG 通路,促进 HIV-1 感染和持续存在
  • 批准号:
    10015198
  • 财政年份:
    2016
  • 资助金额:
    $ 51.31万
  • 项目类别:
HIV co-infection and HCV-induced liver fibrosis in vivo
HIV合并感染和HCV诱导的体内肝纤维化
  • 批准号:
    8383475
  • 财政年份:
    2011
  • 资助金额:
    $ 51.31万
  • 项目类别:
HIV co-infection and HCV-induced liver fibrosis in vivo
HIV合并感染和HCV诱导的体内肝纤维化
  • 批准号:
    8584278
  • 财政年份:
    2011
  • 资助金额:
    $ 51.31万
  • 项目类别:
HIV co-infection and HCV-induced liver fibrosis in vivo
HIV合并感染和HCV诱导的体内肝纤维化
  • 批准号:
    8263237
  • 财政年份:
    2011
  • 资助金额:
    $ 51.31万
  • 项目类别:
HIV-1 Replication and Pathogenesis in vivo
HIV-1体内复制和发病机制
  • 批准号:
    8288315
  • 财政年份:
    2009
  • 资助金额:
    $ 51.31万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 51.31万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 51.31万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 51.31万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 51.31万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 51.31万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 51.31万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 51.31万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 51.31万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 51.31万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 51.31万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了